Pfizer logo new 2021

Pfizer Drops Lawsuit Against J&J Over Remicade Biosimilar Coverage

July 23, 2021

Pfizer withdrew a 2017 lawsuit against Johnson & Johnson (J&J) that alleged the company used anticompetitive practices to stop insurance companies from covering Pfizer’s biosimilar of rheumatoid arthritis drug, Remicade (infliximab). 

Pfizer alleged that J&J violated antitrust laws by telling insurers it would withhold certain rebates on Remicade unless they limited their coverage of Pfizer’s biosimilar, Inflectra, which allowed J&J to corner the market on the drug.

The U.S. District Court for the Eastern District of Pennsylvania dismissed the case “with prejudice,” meaning that the court intends for the dismissal to be final in all courts.

View today's stories